L'intérêt à découvert pour Nuwellis donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Nuwellis. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Nuwellis (NASDAQ:NUWE) Stock, Rapport sur les intérêts à découvert

Nuwellis

Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.

Nuwellis Inc

Macro Economic Events

News

Politics

Economics

General

FORD

STLA

President-Elect Donald J. Trump Says Very Serious Tariffs On Mexico, Canada

Guggenheim analyst John Difucci downgrades Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Neutral to Sell and announces $130 price target.

Downgrades

Price Target

Analyst Ratings

PANW

Guggenheim Downgrades Palo Alto Networks to Sell, Announces $130 Price Target

On Tuesday, Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) shared interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors <a href="https://www.benzinga.com/pressreleases/25/01/n42843100/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial-ht-001-delivers-100-success-in-combating" target="_blank" rel="noreferrer noopener">in cancer patients</a>.
Data from the open-label portion of the CLEER-001 trial demonstrated:
<ul>
<li>100% of patients&nbsp;achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.</li>
<li>66% of patients&nbsp;reported reduced pain and itching scores, further enhancing quality of life.</li>
</ul>
All patients maintained their full EGFRi dosage, preserving the cancer treatment&#8217;s full therapeutic effect—a notable improvement compared to past reports showing widespread dose reductions or treatment halts due to skin-related side effects.
The trial uses the proprietary Acneiform Rash Investigator Global Assessment Scale, developed in collaboration with onco-dermatology experts. The scale ensures precise measurement and assessment of skin toxicity improvements.
Robb Knie, CEO of Hoth Therapeutics, said, &#8220;These results are a significant milestone, underscoring HT-001&#8217;s potential to transform patient care by mitigating debilitating skin toxicities while maintaining critical cancer treatments. Our data highlight HT-001&#8217;s strong safety profile and the potential for it to set a new standard of care in this underserved area.&#8221;
No treatment-related adverse effects have been reported, reaffirming HT-001&#8217;s excellent tolerability.
&#8220;These interim findings align with a recent case report of rapid resolution of EGFRi-induced skin conditions using HT-001,&#8221; added Knie. &#8220;As the study progresses, we anticipate further validating these results and are excited about the potential impact HT-001 could have on patient outcomes.&#8221;
Last month, Hoth Therapeutics entered into an exclusive patent license agreement with the U.S. <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42681746/hoth-therapeutics-enters-partnership-with-the-department-of-veterans-affairs-to-develop-obesity-tr" rel="noreferrer noopener">Department of Veterans Affairs (VA)</a>.
Under the terms of the agreement, Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents.
The VA and&nbsp;Emory University&nbsp;have granted Hoth this license to develop the technology further.
Price Action: HOTH stock is up 246.5% at $2.84 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42844053/accentures-new-research-predicts-how-ai-will-reshape-business-by-2025-details" target="_blank" rel="noreferrer noopener">Accenture&#8217;s New Research Predicts How AI Will Reshape Business By 2025: Details</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

HOTH

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Former BitMEX CEO Arthur Hayes has predicted a potential Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price peak in late March 2025, driven by a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41824236/feds-interest-rate-cut-pace-expected-to-slow-economists-weigh-trumps-white-house-re">surge in dollar liquidity</a>.
<h2 class="wp-block-heading">Liquidity Flowing Into The System Is Bullish</h2>
In his latest blog post from Jan. 7, Hayes <a href="https://cryptohayes.medium.com/sasa-0b474e218c5d">argues </a>that a complex interplay of U.S. Federal Reserve policy and Treasury actions will create a favorable environment for crypto gains in the first quarter before facing a possible correction.
Hayes highlights the current liquidity injections stemming from the depletion of the Fed's Reverse Repo Facility (RRP) and the Treasury&#8217;s General Account (TGA). 
According to Hayes, the RRP, "fallen to almost zero," representing an injection of "$237 billion of dollar liquidity in the first quarter". 
He explains that combined with other factors, this results in a "net injection of $57 billion in liquidity" even when factoring the Fed&#8217;s quantitative tightening. 
Hayes also notes that the Treasury will begin &#8220;extraordinary measures&#8221; to fund government expenditures due to the debt ceiling, which will initially lead to spending down its TGA account, creating further positive liquidity.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42840886/bitcoin-spot-etf-inflows-hit-987-million-but-watch-this-mid-january-fiscal-deadline">Bitcoin Spot ETF Inflows Hit $987 Million But Watch This Mid-January Fiscal Deadline</a>
However, Hayes cautions that this positive environment might be temporary.
"The real question is the pace at which the RRP goes from ~$237 billion to zero," and while these funds are flowing into markets, the debt ceiling crisis could turn the tide: "Once default and shutdown are imminent, a last-minute deal will be reached, and the debt ceiling will be raised. 
At that point, the Treasury will be free to borrow on a net basis again and must refill the TGA. This will be dollar liquidity negative."
<h2 class="wp-block-heading">Why The First Quarter Will Be &#8216;Time To Sell&#8217;</h2>
In his analysis, Hayes also addresses the potential impact <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42701446/crypto-industry-anticipates-policy-overhaul-under-trump-administration">of Trump&#8217;s policies</a>, noting that "the sasa of a letdown by team Trump on his proposed pro-crypto and pro-business legislation can be covered by an extremely positive dollar liquidity environment."
However, Hayes remains cautiously optimistic about the first quarter of 2025 as he states that "it will be time to sell in the late stages of the first quarter and chill on the beach&#8230; and wait for positive fiat liquidity conditions to re-emerge in the third quarter." 
Despite recognizing the inherent risks involved, Hayes expresses confidence in the liquidity factors: "I have confidence in the math behind how the RRP and TGA balances will change over time."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42828238/gemini-resolves-cftc-lawsuit-with-5m-settlement-over-bitcoin-futures-misstatements">Gemini Resolves CFTC Lawsuit With $5M Settlement Over Bitcoin Futures Misstatements</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Could Peak By Late March, Arthur Hayes Says: Here's Why

Guggenheim analyst Michael Schmidt maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $33 to $42.

EXEL

Guggenheim Maintains Buy on Exelixis, Raises Price Target to $42

On Tuesday, Pacira BioSciences, Inc.&nbsp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) received FDA clearance to market a new Smart Tip designed to access the medial branch nerves to manage chronic <a target="_blank" href="https://www.benzinga.com//node/42841844" rel="noreferrer noopener">low back pain</a>.
The ioveraº system is a drug-free treatment that relieves pain via cryoneurolysis—a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals.
Pain relief is typically experienced immediately after treatment, lasting for months as the nerve regenerates.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40321378/pain-management-focused-pacira-biosciences-loses-patent-fight-for-key-drug-jp-morga" rel="noreferrer noopener">Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path</a>
To date, the ioveraº portfolio has consisted of either a three-pronged Smart Tip featuring 8.5-mm long 27-gauge needles to treat superficial nerves or a single, 90-mm long, 20-guage Smart Tip ideally suited to treat deeper nerves.
It is most commonly used to treat knee pain but frequently used to manage pain in the hip, shoulder, chest, foot &amp; ankle, and more.
This new, 25-gauge 180-mm Smart Tip will allow for the treatment of deeper nerves, such as the medial branch nerve. It is specifically designed to relieve chronic low back pain associated with facet-mediated pain.
This longer-needle Smart Tip is designed for use through a cannula or introducer, allowing ice ball formation at deeper peripheral nerves.
Annually, 28 to 30 million Americans seek treatment for chronic back pain, yet only 2 to 3 million undergo interventional procedures.
With the introduction of this new iovera° Smart Tip, Pacira aims to address these gaps and elevate the standard of care.
The company adds that the product offers an alternative to conventional treatments, such as radiofrequency ablation, with substantial limitations.
A single-center randomized pilot study of the iovera° system showed:
<ul>
<li>Patients treated with iovera° reported pain scores more than 2 points lower at 180 and 360 days than those treated with RFA on the 0-10 NRS Pain scale.</li>
<li>At 360 days, patients in the iovera° group showed statistically and clinically significant improvements in functional outcomes, as evidenced by average Oswestry Disability Index (ODI) scores improving from moderate to minimal disability.</li>
<li>More iovera° patients expressed satisfaction with their pain management compared to those receiving RFA.</li>
<li>No serious adverse events were observed over the course of the study.</li>
</ul>
Price Action: PCRX stock is up 1.50% at $18.91 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42846580/rpm-international-q2-strong-sales-adjusted-ebit-growth-and-updated-fy25-guidance" target="_blank" rel="noreferrer noopener">Paint &amp; Coating Company RPM Beats Q2 Expectations But Signals Flat Q3; Stock Dips</a></li>
</ul>

PCRX

Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain

WIIM

ACXP

Acurx Pharmaceuticals shares are trading lower after the company announced a $2.5 million registered direct offering.

On Tuesday, MBX Biosciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial of MBX 1416 in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42840108/mbx-biosciences-announces-positive-phase-1-topline-results-for-mbx-1416-for-the-treatment-of-post-" rel="noreferrer noopener">healthy adult volunteers</a>.
MBX 1416 is the company&#8217;s investigational long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, being developed for Post-Bariatric Hypoglycemia (PBH).
PBH is a common and potentially serious complication that can occur after certain types of weight loss surgery.
Trial data:
<ul>
<li>MBX 1416 was generally well-tolerated with a favorable safety profile.</li>
<li>No MBX 1416 dose-related serious adverse events were observed, and most treatment-emergent adverse events were mild or moderate in severity.</li>
<li>In the multiple ascending dose cohort, MBX 1416 median half-life was approximately 90 hours, supporting once-weekly administration, and at steady state the median Tmax was between 36 and 48 hours.</li>
<li>In the multiple ascending dose cohort, MBX 1416 increased GLP-1 within 60 minutes of a mixed meal tolerance test, suggesting a pharmacodynamic (PD) effect in healthy volunteers that may translate into a therapeutic benefit in PBH patients.</li>
<li>Consistent with the known GLP-1 antagonism effect on gastric motility, a slight acceleration of gastric emptying was observed with MBX 1416 based on acetaminophen exposure.  </li>
<li>In the drug-drug interaction portion of the trial, MBX 1416 was observed to have no meaningful effect on rosuvastatin exposure, a commonly prescribed statin.</li>
</ul>
MBX Biosciences intends to discuss these results with the FDA in an End-of-Phase 1 meeting in mid-2025.
Pending alignment with the FDA, a Phase 2 study of MBX 1416 in patients with PBH is anticipated to initiate in the second half of 2025.
Price Action: MBX stock is down 7.22% at $15.11 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42843536/novo-nordisks-sponsorship-deals-with-uk-pharmacies-linked-to-weight-loss-drugs-raise-ethical-concerns" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns</a></li>
</ul>
Photo by Romix Image via Shutterstock

MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action

Stock Split

XTIA

XTI Aerospace Unveils 2025 Growth Strategy Including 1-for-250 Share Consolidation To Strengthen Balance Sheet, Enhance Leadership In VTOL Innovation, And Regain Nasdaq Compliance

Textron's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) short percent of float has risen 22.52% since its last report. The company recently reported that it has 4.40 million shares sold short, which is 2.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.39 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Textron Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736268320_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Textron has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Textron's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Textron's peer group average for short interest as a percentage of float is 3.85%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Textron's Recent Short Interest

Teledyne Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) short percent of float has fallen 10.14% since its last report. The company recently reported that it has 441 thousand shares sold short, which is 1.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teledyne Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736268315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teledyne Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teledyne Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teledyne Technologies's peer group average for short interest as a percentage of float is 7.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Teledyne Technologies?

FedEx's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) short percent of float has fallen 11.11% since its last report. The company recently reported that it has 3.53 million shares sold short, which is 1.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>FedEx Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736268310_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for FedEx has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing FedEx's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, FedEx's peer group average for short interest as a percentage of float is 3.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into FedEx's Recent Short Interest

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 10.57% on an annualized basis producing an average annual return of 18.97%. Currently, Illumina has a market capitalization of $22.18 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $3,290.99 today based on a price of $139.84 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736268307_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ILMN

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Redburn Atlantic analyst Hamilton Faber upgrades Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) from Neutral to Buy and raises the price target from $100 to $147.

Upgrades

Redburn Atlantic Upgrades Walt Disney to Buy, Raises Price Target to $147

<a href="https://www.bloomberg.com/live/us" title="https://www.bloomberg.com/live/us">https://www.bloomberg.com/live/us</a>

Events

NVDA

Live On BloombergTV, Nvidia CEO Jensen Huang Discusses New Graphics Cards Announced At CES Event

William Blair analyst Margaret Andrew downgrades Inari Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) from Outperform to Market Perform.

NARI

William Blair Downgrades Inari Medical to Market Perform

KOLD

President-Elect Trump Says I Will Revoke Offshore Oil, Gas Drilling Ban In Vast Areas On Day One

Mass media and entertainment&nbsp;companies Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) and Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) have reached a deal to renew their distribution agreements, ensuring continued access to a range of premium <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42843130/paramount-and-comcast-announce-multi-year-distribution-agreements" rel="noreferrer noopener">content for Xfinity customers.</a>
The renewed multi-year contracts will maintain the availability of Paramount&#8217;s popular channels, including CBS, BET, Comedy Central, and Nickelodeon, as well as streaming platforms such as Paramount+, Pluto TV, and BET+. Terms of the agreement were not disclosed.
Comcast customers will also be able to access Paramount+ with SHOWTIME as part of the agreement.
&#8220;This agreement gives us the ability to offer customers more choice and flexibility in what they want to watch and how they want to watch it,&#8221; said John Dixon, Senior Vice President, Entertainment, Comcast Cable.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42816545/fubotv-and-disney-near-merger-to-create-second-largest-digital-tv-provider-shares-soar-report" rel="noreferrer noopener">From Rivalry To Revolution: FuboTV To Combine With Disney&#8217;s Hulu + Live TV, Settles Litigation</a>
Ray Hopkins, President of Paramount Distribution, said, &#8220;This new deal ensures that our dynamic portfolio of popular brands and premium programming continue to reach and entertain our valued audiences everywhere.&#8221;
Paramount reported third-quarter revenue of $6.73 billion, <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41844296/paramount-q3-streaming-gains-operating-income-declines" rel="noreferrer noopener">down 6% year-over-year</a>.&nbsp;
However, Paramount+&#8217;s revenue increased 25% year over year, ending the quarter with 72 million subscribers, up 3.5 million.
Price Action: CMCSA shares are trading lower by 0.23% at $37.41 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42839556/uber-and-nvidia-partner-on-ai-technology-for-autonomous-cars" target="_blank" rel="noreferrer noopener">Uber And NVIDIA Partner On AI Technology For Autonomous Cars</a></li>
</ul>
Photo via Shutterstock.

Entertainment

Equities

Contracts

CMCSA

PARA

Paramount, Comcast Renew Major Distribution Deal: Details

NVIDIA shares are trading lower as investors possibly react to product announcements at CES 2025.

Before Mark Cuban was a billionaire, before <a href="https://www.benzinga.com/personal-finance/24/09/40819379/mark-cuban-personally-called-nba-fans-saying-mavericks-games-are-cheaper-than-taking-the-family-">courtside seats to the Dallas Mavericks</a> became his office and before he was dishing out advice and cash on Shark Tank, he was just another guy trying to figure life out. At 27, Cuban wasn't living in the lap of luxury but he was starting to see the fruits of his hard work.
According to a 2012 Business Insider article covering excerpts from his book, Cuban had upgraded from the cheap polyester suits he'd been sporting for years, was finally making "twice his age," and was engaged to be married. Life seemed to be coming together.
Then, it all unraveled.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Cuban recalls spending his entire <a href="https://www.benzinga.com/24/12/42721109/mark-cuban-once-said-credit-card-users-dont-want-to-be-rich-now-us-credit-card-defaults-have-skyrocketed-to-highest-levels-since-2008-financial-crisis">$7,500 life savings</a> on an engagement ring, only for his fiancée to lose it in a movie theater. "A couple of months later, the relationship broke up," he explained. Suddenly, his carefully built future felt like it had gone up in smoke. But that moment of personal failure taught him something essential: the only thing you can truly control in life is effort.
"In sports, the only thing a player can truly control is effort," Cuban says. "The same applies to business. The only thing any entrepreneur, salesperson or anyone in any position can control is their effort."
With nothing left to do but focus on his business, Cuban made a decision: he would recommit to working <a href="https://www.benzinga.com/personal-finance/24/09/40920706/billionaire-mark-cuban-says-his-credit-was-so-bad-radio-shack-denied-him-if-you-use-credit-cards">harder and smarter than ever before</a>.
See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
"I had to kick myself in the a&#x2A;&#x2A; and recommit to getting up early, staying up late and consuming everything I possibly could to get an edge," he said. "It meant making sure that every hour of the day that I could contact a customer was selling time and when customers were sleeping, I was doing things that prepared me to make more sales and to make my company better."
But the effort, Cuban stresses, isn't just about clocking long hours. He cautions against mistaking time spent for productivity. "It would have been easy to judge effort by how many hours a day passed while I was at work," he said. "That's the worst way to measure effort."
Instead, Cuban set clear, results-driven goals. He asked himself:
• What do I need to do to close this account?
• What do I need to do to win this segment of business?
• What do I need to do to understand this technology or that business better than anyone?
• Where can I find an edge and how am I going to get there?
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
"The one requirement for success in our business lives is effort. Either you make the commitment to get results or you don't," Cuban said.
That mentality – effort measured by results, not time – became the foundation of Cuban's success. It drove him to build his first company, MicroSolutions and sell it for $6 million. It helped him navigate failure and it keeps him sharp today.
Cuban's story of the lost ring and the failed relationship isn't just a tale of personal heartbreak. It's a reminder that even when life throws you a curveball, you still have the power to control your response. The billionaire didn't sit around mourning his lost savings or broken engagement; he doubled his effort, pushed himself to improve and used those lessons to build a business empire.
And as Cuban would tell you today, it's not about working longer hours – it's about working smarter, setting goals and doing whatever it takes to reach them. If you're making New Year's resolutions this year, he'd likely suggest starting with the one thing you can always control: your effort. And if your financial goals need a boost, <a href="https://www.benzinga.com/money/are-you-rich">talking to an advisor</a> might be the smartest move you make all year.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

Mark Cuban Spent $7,500 Life Savings On An Engagement Ring, Fiancée Lost It and They Broke Up – But He Learned Effort Is All You Can Control

Nuwellis Q3 Earnings Preview

Reports Q3 revenue $2.367M vs $2.412M last year. "We commend the hard work and dedication of the Nuwellis (NUWE) team, fueling steady market adopti...

Nuwellis reports Q3 EPS $1.74 vs ($63.27) last year

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Tesla&nbsp;(TSLA) up 6% after Barron's wrote Elon Musk c...

Morning Movers: Cigna climbs after confirming not pursuing Humana deal

Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript

Nuwellis, Inc. ( ($NUWE) ) has released its Q3 earnings. Here is a breakdown of the information Nuwellis, Inc. presented to its investors. Nuwellis...

Nuwellis, Inc. Reports Strong Q3 Financial Performance

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Nuwellis (NUWE – Research Report). The company's shar...

Maxim Group Remains a Hold on Nuwellis (NUWE)

17:25 EST Nuwellis (NUWE) files to sell 3.73M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mar...

Nuwellis files to sell 3.73M shares of common stock for holders

Nuwellis files for secondary stock offering

Nuwellis (NUWE) announced that the Company received formal written notice from The Nasdaq Stock Market that the Company has regained compliance wit...

Nuwellis regains compliance with Nasdaq listing requirements

The U.S. Food and Drug Administration said it is aware that Nuwellis (NUWE) has issued a letter to affected health care providers recommending cert...

FDA says aware Nuwellis recalling certain blood circuit lots

ARMK

ISPR

LINC

MNDY

NUWE

NUWEW

SPNS

TSLA

Press Releases

New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy

Comments

Nuwellis

Intérêt court

Nuwellis (NASDAQ:NUWE) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL